FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare
About | Sample | Privacy
Related Topics >> Phase III | Somaxon | CEO | smoking cessation

Somaxon CEO resigns

Somaxon CEO Kenneth M. Cohen has announced this resignation, effective December 31, 2007. The company's non-executive board chairman David F. Hale will serve as interim CEO until a permanent replacement for Cohen is hired. Specific reasons for Cohen's resignation were not outlined in the announcement, though the company noted that "management changes are part of a transition plan." Somaxon is based in San Diego, CA and is developing psychiatry and neurology treatments.

- see Somaxon's release

Related Articles:
Somaxon touts latest Phase III results for Silenor. Report
Somaxon reveals mid-stage data on smoking cessation. Report

More stories about Phase III   Somaxon   CEO   smoking cessation  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

What is 16 + 11?
To combat spam, please solve the math question above.